Qiang Dong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Qiang Dong has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
Luchen Yang
Department of Urology Institute of Urology, West China Hospital of Sichuan University Chengdu China
38 shared publicationsPan Song
33 shared publicationsJing Zhou
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China
28 shared publicationsZhenghuan Liu
Department of Urology, West China Hospital, Sichuan University, Chengdu, PR China
25 shared publicationsKai Ma
Department of Urology Institute of Urology, West China Hospital of Sichuan University Chengdu China
19 shared publicationsZhufeng Peng
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, PR China
18 shared publications
Latest Publications
- 20 October 2026
- Published by Springer Nature in Seminars in Immunopathology
- Vol. 48 (1) , 23
Lineage plasticity–driven immunometabolic state transitions in advanced prostate cancer: biomarkers and therapeutic stratification
Advanced prostate cancer is commonly described as immunologically cold, yet that label obscures a disease continually remodelled by treatment. Androgen-receptor (AR) pathway inhibition, chemotherapy, DNA-damage-directed therapy and radioligand treatment select resistant clones while altering lineage identity, metabolic dependence, antigen presentation and metastatic niches. AR-high, AR-low, double-negative, amphicrine and treatment-emergent neuroendocrine phenotypes are therefore better viewed as evolving immunometabolic states than as fixed histologies. Here, we develop a lineage–metabolism–immunity framework that integrates metastatic biopsies, longitudinal sampling, single-cell and spatial analyses, functional imaging and mechanistic prostate cancer models. Lineage determines which metabolic programmes remain available; tumour, stromal and immune cells then compete for nutrients and exchange metabolites that shape antigen presentation, myeloid suppression and lymphocyte function. We focus on glucose and lactate, lipids, amino acids, hypoxia–adenosine signalling and epigenetically active metabolites, while separating patient evidence from causal prostate cancer models and pan-cancer inference. The framework reframes three clinical tasks: identifying the state driving progression, recognising transitions under therapy and selecting combinations that relieve the dominant immune bottleneck without disabling effector cells. Translation will require longitudinal, lesion-aware measurements that connect lineage markers to functional evidence of metabolic dependence and immune context. The goal is not a universal metabolic target, but a tractable intervention matched to the tumour state, metastatic site and therapeutic window.
- 20 October 2026
- Published by Springer Nature in Seminars in Immunopathology
- Vol. 48 (1) , 23
Lineage plasticity–driven immunometabolic state transitions in advanced prostate cancer: biomarkers and therapeutic stratification
Advanced prostate cancer is commonly described as immunologically cold, yet that label obscures a disease continually remodelled by treatment. Androgen-receptor (AR) pathway inhibition, chemotherapy, DNA-damage-directed therapy and radioligand treatment select resistant clones while altering lineage identity, metabolic dependence, antigen presentation and metastatic niches. AR-high, AR-low, double-negative, amphicrine and treatment-emergent neuroendocrine phenotypes are therefore better viewed as evolving immunometabolic states than as fixed histologies. Here, we develop a lineage–metabolism–immunity framework that integrates metastatic biopsies, longitudinal sampling, single-cell and spatial analyses, functional imaging and mechanistic prostate cancer models. Lineage determines which metabolic programmes remain available; tumour, stromal and immune cells then compete for nutrients and exchange metabolites that shape antigen presentation, myeloid suppression and lymphocyte function. We focus on glucose and lactate, lipids, amino acids, hypoxia–adenosine signalling and epigenetically active metabolites, while separating patient evidence from causal prostate cancer models and pan-cancer inference. The framework reframes three clinical tasks: identifying the state driving progression, recognising transitions under therapy and selecting combinations that relieve the dominant immune bottleneck without disabling effector cells. Translation will require longitudinal, lesion-aware measurements that connect lineage markers to functional evidence of metabolic dependence and immune context. The goal is not a universal metabolic target, but a tractable intervention matched to the tumour state, metastatic site and therapeutic window.
- 20 October 2026
- Published by Wiley in BJU International
Androgen driven organoids for the male urogenital system
Androgen signalling plays a central role in the development and function of the male urogenital system, including the adrenal gland, prostate, and testis. Disruption of the androgen axis underlies diseases ranging from infertility to castration‐resistant prostate cancer, yet current models fail to fully display its multi‐organ and hormone‐driven complexity. Organoid systems provide a promising platform to model androgen‐responsive tissues while preserving three‐dimensional structure and cellular heterogeneity, with the ability for long‐term culture and cryopreservation. Recent advances have enabled the generation of prostate, testicular, and adrenocortical organoids, offering new opportunities to study androgen receptor signalling, steroidogenesis, and lineage plasticity. Here, we review androgen‐driven organoids across the male urogenital axis and discuss emerging strategies to recapitulate endocrine crosstalk. Despite these advances, current models remain reductionist and lack systemic integration. Future efforts toward multi‐organ platforms and engineered microenvironments may enable the elucidation of the role of androgen signalling in physiological conditions and disease development.
- 20 October 2026
- Published by Wiley in BJU International
Androgen driven organoids for the male urogenital system
Androgen signalling plays a central role in the development and function of the male urogenital system, including the adrenal gland, prostate, and testis. Disruption of the androgen axis underlies diseases ranging from infertility to castration‐resistant prostate cancer, yet current models fail to fully display its multi‐organ and hormone‐driven complexity. Organoid systems provide a promising platform to model androgen‐responsive tissues while preserving three‐dimensional structure and cellular heterogeneity, with the ability for long‐term culture and cryopreservation. Recent advances have enabled the generation of prostate, testicular, and adrenocortical organoids, offering new opportunities to study androgen receptor signalling, steroidogenesis, and lineage plasticity. Here, we review androgen‐driven organoids across the male urogenital axis and discuss emerging strategies to recapitulate endocrine crosstalk. Despite these advances, current models remain reductionist and lack systemic integration. Future efforts toward multi‐organ platforms and engineered microenvironments may enable the elucidation of the role of androgen signalling in physiological conditions and disease development.
- Open Access
- 28 July 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Comparative diagnostic accuracy of PSMA-PET versus conventional imaging for Initial T/N/M staging of intermediate- to high-risk prostate cancer: a patient-level paired bivariate meta-analysis
To compare the patient-level diagnostic accuracy of PSMA-PET with multiparametric magnetic resonance imaging (mpMRI), computed tomography (CT), and bone sc
- 28 July 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessComparative diagnostic accuracy of PSMA-PET versus conventional imaging for Initial T/N/M staging of intermediate- to high-risk prostate cancer: a patient-level paired bivariate meta-analysis
To compare the patient-level diagnostic accuracy of PSMA-PET with multiparametric magnetic resonance imaging (mpMRI), computed tomography (CT), and bone sc
- Open Access
- 27 July 2026
- Published by Elsevier in SSRN Electronic Journal
When Does Artificial Intelligence Add Value in Detecting Clinically Significant Prostate Cancer? A Systematic Review and Meta-Analysis across MRI and Ultrasound Workflows and Reader Expertise
Background: Artificial intelligence (AI) is increasingly used in prostate imaging, but its clinical value may differ by imaging modality, reader expertise and implementation workflow. To compare the diagnostic performance of AI and physician interpretation for patient-level detection of clinically significant prostate cancer (csPCa) on MRI and ultrasound.Methods: In this systematic review and meta-analysis, PubMed, Embase, CENTRAL, and Scopus were searched for studies comparing standalone or AI-assisted prostate MRI or ultrasound interpretation with physician assessment for patient-level clinically significant prostate cancer detection. Studies were grouped as standalone MRI AI versus radiologists, AI-assisted MRI interpretation versus physicians alone, and ultrasound AI. Bivariate random-effects diagnostic accuracy models on the logit scale were used to estimate pooled sensitivity, specificity, and model-based absolute differences.Findings: Twenty-six studies were included, comprising 13 standalone MRI AI studies with 3237 patients, eight AI-assisted MRI studies with 2325 patients, and five ultrasound AI studies with 632 patients. For MRI-based csPCa detection, AI showed broadly comparable overall performance to radiologists, with sensitivity of 92.6% versus 94.5% and specificity of 52.3% versus 45.7%. AI did not outperform expert readers, with no significant difference in either sensitivity or specificity. In routine or mixed-reader settings, AI significantly improved specificity compared with radiologists (+19.9 percentage points; P=.004), while sensitivity remained similar. AI-assisted interpretation produced the strongest clinically actionable MRI signal among less-experienced readers, improving both sensitivity (+6.2 percentage points; P<.001) and specificity (+9.2 percentage points; P<.001). In ultrasound studies with human-reader comparisons, AI showed higher sensitivity than human readers (+13.4 percentage points; P<.001), although the number of ultrasound studies was limited.Interpretatio: Prostate imaging AI showed modality- and expertise-specific performance rather than uniform suneriority. In MRI, AI was broadly comparable to radiologists overall but did not outperform expert readers; its clearest gain was improved specificity in routine or mixed-reader settings. The strongest clinically actionable MRI signal was augmentation of less-experienced readers. In ultrasound, AI showed a distinct sensitivity advantage, but current evidence remains limited and requires prospective validation.
- 27 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessWhen Does Artificial Intelligence Add Value in Detecting Clinically Significant Prostate Cancer? A Systematic Review and Meta-Analysis across MRI and Ultrasound Workflows and Reader Expertise
Background: Artificial intelligence (AI) is increasingly used in prostate imaging, but its clinical value may differ by imaging modality, reader expertise and implementation workflow. To compare the diagnostic performance of AI and physician interpretation for patient-level detection of clinically significant prostate cancer (csPCa) on MRI and ultrasound.Methods: In this systematic review and meta-analysis, PubMed, Embase, CENTRAL, and Scopus were searched for studies comparing standalone or AI-assisted prostate MRI or ultrasound interpretation with physician assessment for patient-level clinically significant prostate cancer detection. Studies were grouped as standalone MRI AI versus radiologists, AI-assisted MRI interpretation versus physicians alone, and ultrasound AI. Bivariate random-effects diagnostic accuracy models on the logit scale were used to estimate pooled sensitivity, specificity, and model-based absolute differences.Findings: Twenty-six studies were included, comprising 13 standalone MRI AI studies with 3237 patients, eight AI-assisted MRI studies with 2325 patients, and five ultrasound AI studies with 632 patients. For MRI-based csPCa detection, AI showed broadly comparable overall performance to radiologists, with sensitivity of 92.6% versus 94.5% and specificity of 52.3% versus 45.7%. AI did not outperform expert readers, with no significant difference in either sensitivity or specificity. In routine or mixed-reader settings, AI significantly improved specificity compared with radiologists (+19.9 percentage points; P=.004), while sensitivity remained similar. AI-assisted interpretation produced the strongest clinically actionable MRI signal among less-experienced readers, improving both sensitivity (+6.2 percentage points; P<.001) and specificity (+9.2 percentage points; P<.001). In ultrasound studies with human-reader comparisons, AI showed higher sensitivity than human readers (+13.4 percentage points; P<.001), although the number of ultrasound studies was limited.Interpretatio: Prostate imaging AI showed modality- and expertise-specific performance rather than uniform suneriority. In MRI, AI was broadly comparable to radiologists overall but did not outperform expert readers; its clearest gain was improved specificity in routine or mixed-reader settings. The strongest clinically actionable MRI signal was augmentation of less-experienced readers. In ultrasound, AI showed a distinct sensitivity advantage, but current evidence remains limited and requires prospective validation.
- Open Access
- 1 July 2026
- Published by Springer Nature in Research Square
Bivariate Diagnostic Paired Meta-Analysis at the Patient Level: Direct Validation of PSMA-PET against Conventional Imaging Across All T/N/M Staging Dimensions in Primary Intermediate- to High-Risk Prostate Cancer
Purpose Currently, the clinical value of prostate-specific membrane antigen-ligand positron emission tomography (PSMA-PET) in the diagnosis and initial staging of prostate cancer patients has gained clinical recognition. However, previous assessments have predominantly provided general overviews, lacking updated systematic evidence derived from direct comparative studies. Our study aims to synthesize the existing literature to perform a head-to-head comparison of the diagnostic efficacy between PSMA-PET and conventional imaging modalities in initial staging, using histopathology as the reference standard. These conventional methods include multiparametric magnetic resonance imaging (mpMRI), computed tomography (CT), and bone scintigraphy (BS), with comparisons encompassing primary tumor (T stage), regional lymph nodes (N stage), and distant bone metastases (M stage). Methods We conducted a systematic search from inception to October 2025 across PubMed, Embase, Web of Science, and Scopus databases using predefined search terms, including "PSMA PET," "primary staging," and "prostate cancer." Subsequently, two independent reviewers evaluated all studies against predetermined eligibility criteria, extracted relevant data, and assessed the quality of evidence. Any discrepancies were resolved by a third reviewer. Only studies in which patients underwent both PSMA-PET and conventional imaging modalities (CIM) with imaging findings validated against histopathology or a composite reference standard were included. Quality assessment was performed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) checklist and its comparative review extension (QUADAS-C). Statistical analysis was conducted using the bivariate composite likelihood (CL) method, with imaging modality incorporated as a covariate in the meta-regression model; statistical significance was determined using the likelihood ratio test. Results A total of 43 articles comprising 4,023 patients were included in this study. Our findings demonstrated that, compared with mpMRI, PSMA PET/CT and PSMA PET/MRI exhibited sensitivities of 51.6% versus 59.2% and 63.1% versus 51.0%, respectively, and specificities of 69.1% versus 76.1% and 74.1% versus 79.0%, respectively, for extraprostatic extension (EPE). For seminal vesicle invasion (SVI), the sensitivities were 53.6% versus 51.4% and 54.8% versus 48.3%, respectively, with specificities of 87.2% versus 91.1% and 94.3% versus 96.1%, respectively. Regarding lymph node staging, PSMA-PET demonstrated superior sensitivity and specificity compared with both mpMRI (69.9% versus 39.4%, 90.4% versus 88.5%) and CT (66.1% versus 35.1%, 97.2% versus 78.2%). For bone metastases, PSMA-PET exhibited significantly higher sensitivity and specificity regardless of whether single-photon emission computed tomography was concurrently employed (95.8% versus 76.2%, 92.8% versus 77.4%). Post-hoc subgroup analyses identified PSMA-PET scanner type and time interval exceeding one month as sources of heterogeneity. Sensitivity analyses further indicated that MRI magnetic field strength represented a potential influencing factor. Conclusions This study demonstrates that although PSMA-PET currently shows comparable performance to guideline-recommended multiparametric magnetic resonance imaging (mpMRI) for intraprostatic tumor local staging, its significantly superior diagnostic performance in lymph node and bone metastasis staging supports its use as the preferred method for initial staging of prostate cancer (PCa). Furthermore, we found that PSMA-PET/MRI exhibited higher sensitivity in detecting extraprostatic extension (EPE), providing a reference basis for optimizing local staging strategies in prostate cancer.
- 1 July 2026
- Published by Springer Nature in Research Square
Open AccessBivariate Diagnostic Paired Meta-Analysis at the Patient Level: Direct Validation of PSMA-PET against Conventional Imaging Across All T/N/M Staging Dimensions in Primary Intermediate- to High-Risk Prostate Cancer
Purpose Currently, the clinical value of prostate-specific membrane antigen-ligand positron emission tomography (PSMA-PET) in the diagnosis and initial staging of prostate cancer patients has gained clinical recognition. However, previous assessments have predominantly provided general overviews, lacking updated systematic evidence derived from direct comparative studies. Our study aims to synthesize the existing literature to perform a head-to-head comparison of the diagnostic efficacy between PSMA-PET and conventional imaging modalities in initial staging, using histopathology as the reference standard. These conventional methods include multiparametric magnetic resonance imaging (mpMRI), computed tomography (CT), and bone scintigraphy (BS), with comparisons encompassing primary tumor (T stage), regional lymph nodes (N stage), and distant bone metastases (M stage). Methods We conducted a systematic search from inception to October 2025 across PubMed, Embase, Web of Science, and Scopus databases using predefined search terms, including "PSMA PET," "primary staging," and "prostate cancer." Subsequently, two independent reviewers evaluated all studies against predetermined eligibility criteria, extracted relevant data, and assessed the quality of evidence. Any discrepancies were resolved by a third reviewer. Only studies in which patients underwent both PSMA-PET and conventional imaging modalities (CIM) with imaging findings validated against histopathology or a composite reference standard were included. Quality assessment was performed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) checklist and its comparative review extension (QUADAS-C). Statistical analysis was conducted using the bivariate composite likelihood (CL) method, with imaging modality incorporated as a covariate in the meta-regression model; statistical significance was determined using the likelihood ratio test. Results A total of 43 articles comprising 4,023 patients were included in this study. Our findings demonstrated that, compared with mpMRI, PSMA PET/CT and PSMA PET/MRI exhibited sensitivities of 51.6% versus 59.2% and 63.1% versus 51.0%, respectively, and specificities of 69.1% versus 76.1% and 74.1% versus 79.0%, respectively, for extraprostatic extension (EPE). For seminal vesicle invasion (SVI), the sensitivities were 53.6% versus 51.4% and 54.8% versus 48.3%, respectively, with specificities of 87.2% versus 91.1% and 94.3% versus 96.1%, respectively. Regarding lymph node staging, PSMA-PET demonstrated superior sensitivity and specificity compared with both mpMRI (69.9% versus 39.4%, 90.4% versus 88.5%) and CT (66.1% versus 35.1%, 97.2% versus 78.2%). For bone metastases, PSMA-PET exhibited significantly higher sensitivity and specificity regardless of whether single-photon emission computed tomography was concurrently employed (95.8% versus 76.2%, 92.8% versus 77.4%). Post-hoc subgroup analyses identified PSMA-PET scanner type and time interval exceeding one month as sources of heterogeneity. Sensitivity analyses further indicated that MRI magnetic field strength represented a potential influencing factor. Conclusions This study demonstrates that although PSMA-PET currently shows comparable performance to guideline-recommended multiparametric magnetic resonance imaging (mpMRI) for intraprostatic tumor local staging, its significantly superior diagnostic performance in lymph node and bone metastasis staging supports its use as the preferred method for initial staging of prostate cancer (PCa). Furthermore, we found that PSMA-PET/MRI exhibited higher sensitivity in detecting extraprostatic extension (EPE), providing a reference basis for optimizing local staging strategies in prostate cancer.
- Open Access
- 26 September 2025
- Published by International Society of Global Health in Journal of Global Health
- Vol. 15, 04228
Phenotypic and genetically predicted leukocyte telomere length and prostate cancer risk: results from a large-scale longitudinal cohort study
Leukocyte telomere length (LTL) plays a crucial role in human biology, especially for preserving genomic integrity and shielding chromosomal ends from degradation [1]. Telomeres are repeated nucleotide sequences at the ends of chromosomes, and they progressively shorten with each cell division [2]. This process of shortening acts as a biological clock, signalling the age of […]
- 26 September 2025
- Published by International Society of Global Health in Journal of Global Health
- Vol. 15, 04228
Open AccessPhenotypic and genetically predicted leukocyte telomere length and prostate cancer risk: results from a large-scale longitudinal cohort study
Leukocyte telomere length (LTL) plays a crucial role in human biology, especially for preserving genomic integrity and shielding chromosomal ends from degradation [1]. Telomeres are repeated nucleotide sequences at the ends of chromosomes, and they progressively shorten with each cell division [2]. This process of shortening acts as a biological clock, signalling the age of […]
- 12 August 2025
- Published by Elsevier in Phytomedicine
- Vol. 147, 157165
Elucidating the therapeutic mechanisms of resveratrol in benign prostatic hyperplasia via an integrated strategy of network pharmacology, multi-omics and molecular biology
- 12 August 2025
- Published by Elsevier in Phytomedicine
- Vol. 147, 157165
Elucidating the therapeutic mechanisms of resveratrol in benign prostatic hyperplasia via an integrated strategy of network pharmacology, multi-omics and molecular biology
- 8 December 2024
- Published by Elsevier in Environmental Pollution
- Vol. 366, 125503
DEHP-mediated oxidative stress leads to impaired testosterone synthesis in Leydig cells through the cAMP/PKA/SF-1/StAR pathway
- 8 December 2024
- Published by Elsevier in Environmental Pollution
- Vol. 366, 125503
DEHP-mediated oxidative stress leads to impaired testosterone synthesis in Leydig cells through the cAMP/PKA/SF-1/StAR pathway
- Open Access
- 22 November 2024
- Published by International Society of Global Health in Journal of Global Health
- Vol. 14, 04242
Circulating levels of blood biomarkers and risk of benign prostatic hyperplasia: Results from two large cohorts in Europe and East Asia
Benign prostatic hyperplasia (BPH) is distinguished by symptoms such as urinary incontinence and retention, standing as the most prevalent urologic condition among older men. Its onset typically becomes evident upon reaching the age of 45, with a discernible increase in incidence over time, with approximately 25% of men in their fifties, 33% among those in […]
- 22 November 2024
- Published by International Society of Global Health in Journal of Global Health
- Vol. 14, 04242
Open AccessCirculating levels of blood biomarkers and risk of benign prostatic hyperplasia: Results from two large cohorts in Europe and East Asia
Benign prostatic hyperplasia (BPH) is distinguished by symptoms such as urinary incontinence and retention, standing as the most prevalent urologic condition among older men. Its onset typically becomes evident upon reaching the age of 45, with a discernible increase in incidence over time, with approximately 25% of men in their fifties, 33% among those in […]